Researcher
Peter Van Dam
- Research Expertise:Translational investigations in breat and cervical cancer Immune environment in inflammatory breast cancer and cervical cancer Effect of Denosumab on the immune environment of cervical cancer Quality control of cancer treatment Telemonitoring of sidde effects of cancer treatment Cognitive impairment after cancer treatment
- Keywords:T CYTOTOXIC LYMPHOCYTE, T HELPER LYMPHOCYTE, Medicine
- Disciplines:Cancer biology, Cancer diagnosis, Cancer therapy
- Research techniques:Immunohistochemical staining Flow cytometry RNA seq
- Users of research expertise:Other interested groups
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Member
From1 Feb 2014 → 31 Dec 2018
Projects
1 - 10 of 10
- Establishing patient-derived organoids to rationally design therapies for patients with inflammatory breast cancerFrom1 Nov 2023 → TodayFunding: Nonprofit institution or equivalents
- Reinvigorating the antitumor immunity in human breastand cervical cancer with an innovative RANK(L) targeted combination strategy.From1 Nov 2021 → TodayFunding: Nonprofit institution or equivalents
- Development and validation of a novel rationally designed immunotherapeutic combination strategy built upon targeting RANK(L) for cervical cancer.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Acquired immunity and immunologic aspects of SARS-CoV-2 infection a population of patients and healthcare workers in Multidisciplinary Oncologic Centres. (MOCOR-Study).From1 Jun 2020 → 31 May 2021Funding: BOF - projects
- Unveiling the drug repurposing versatility of denosumab in the battle against human cervical cancer.From1 Jan 2020 → 31 Dec 2020Funding: Nonprofit institution or equivalents
- Integrated Personalized & Precision Oncology Network (IPPON).From1 Jan 2020 → TodayFunding: BOF - research organisations, Fund Recuperation Fiscal Exemption
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2018 → 30 Sep 2020Funding: FWO fellowships
- RANK signaling and checkpoint inhibition.From15 Sep 2018 → 14 Sep 2021Funding: Nonprofit institution or equivalents
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
- Characterization of the stromal component in inflammatory breast cancer.From15 Jan 2016 → 14 Jan 2017Funding: Nonprofit institution or equivalents
Publications
11 - 20 of 108
- The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres(2022)
Authors: Peter Van Dam, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Cynthia Aristei, Laura Biganzoli, Maria J. Cardoso, Kwok L. Cheung, Giuseppe Curigliano, Jakob De Vries, et al.
Pages: 72 - 79 - Breast cancer and breast cancer screening in Niger(2022)
Authors: Abdou Aissami, Guido Van Hal, Peter Van Dam
Number of pages: 74 - Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors(2022)
Authors: Angelina Konnova, Fien De Winter, Akshita Gupta, An Hotterbeekx, Matilda Berkell, Laure-Anne Teuwen, Greetje Vanhoutte, Silke Raats, Isolde Van der Massen, Yana Debie, et al.
Pages: 1 - 10 - Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in cancer patients(2022)
Authors: Yana Debie, Timon Vandamme, Maria E. Goossens, Peter Van Dam, Marc Peeters
Pages: 177 - 179 - Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer(2022)
Authors: Simone N. Koole, Philip C. Schouten, Jan Hauke, Roel J.C. Kluin, Petra Nederlof, Lisa K. Richters, Gabriele Krebsbach, Karolina Sikorska, Maartje Alkemade, Mark Opdam, et al.
Pages: 1394 - 1404 - Evaluation of a new online cognitive assessment tool in breast cancer survivors with cognitive impairment(2022)
Authors: Anne Bellens, Ella Roelant, Marc Peeters, Peter Van Dam
Pages: 21 - 31 - Expression of SARS-CoV-2-related surface proteins in non-small-cell lung cancer patients and the influence of standard of care therapy(2022)
Authors: Christophe Deben, Maxim Le Compte, Vasiliki Siozopoulou, Hilde Lambrechts, Christophe Hermans, Ho Wa Lau, Manon Huizing, Kevin Lamote, Jeroen Hendriks, Peter Van Dam, et al.
Pages: 1 - 15 - Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer(2022)
Authors: Francesco Schettini, Sergio Venturini, Mario Giuliano, Matteo Lambertini, David J. Pinato, Concetta Elisa Onesti, Pietro De Placido, Nadia Harbeck, Diana Lüftner, Hannelore Denys, et al.
Pages: 1 - 13 - Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients(2022)
Authors: Peter Van Dam, Yana Debie, Laure-Anne Teuwen, L. Verbruggen, Greetje Vanhoutte, Lieselot Croes, Christof Vulsteke, Sébastien Anguille, Timon Vandamme, Marc Peeters
Pages: 1 - 2 - ESO-ESSO-ESTRO multidisciplinary course in oncology for medical students(2022)
Authors: Nicholas Pavlidis, Radoslaw Madry, Marc Peeters, Sergio Sandrucci, Janina Markowska, Fedro Peccatori, Alberto Costa, Jesper Grau Eriksen, Umberto Ricardi, Richard Poetter, et al.
Pages: 1239 - 1244